GSA Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

GSA Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$323K	Buy	173,844 +59,588	+52%	+$98.1K	0.02%	1257
2026 Q1	$185K	Buy	+114,256	New	+$187K	0.01%	1474
2025 Q2	–	Sell	-14,683	Closed	-$20K	–	2071
2025 Q1	$20K	Buy	+14,683	New	+$31.3K	﹤0.01%	1585
2023 Q4	–	Sell	-74,084	Closed	-$96K	–	1837
2023 Q3	$96K	Buy	74,084 +30,248	+69%	+$47.6K	0.01%	1392
2023 Q2	$71K	Buy	+43,836	New	+$85.6K	0.01%	1402
2023 Q1	–	Sell	-21,514	Closed	-$80K	–	1846
2022 Q4	$80K	Buy	+21,514	New	+$28.2K	0.01%	1329
2021 Q4	–	Sell	-137,003	Closed	-$1.15M	–	1719
2021 Q3	$1.15M	Buy	137,003 +75,714	+124%	+$495K	0.12%	239
2021 Q2	$413K	Buy	61,289 +35,137	+134%	+$227K	0.05%	753
2021 Q1	$173K	Sell	26,152 -21,473	-45%	-$110K	0.03%	936
2020 Q4	$200K	Buy	+47,625	New	+$201K	0.03%	994
2019 Q4	–	Sell	-11,231	Closed	-$65K	–	1667
2019 Q3	$65K	Buy	+11,231	New	+$89.7K	0.01%	1304

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

GSA Capital Partners's PRQR Position: Q2 2026 in Review

GSA Capital Partners increased its ProQR Therapeutics (PRQR) stake by 52% in Q2 2026, buying an estimated $98.1K and bringing the position to 173,844 shares worth $323K. The position accounts for 0.02% of the portfolio, ranked #1257.

GSA Capital Partners first reported a position in PRQR in Q3 2019 and has held it in 11 quarters since. The position peaked at $1.15M in Q3 2021. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

GSA Capital Partners held 173,844 shares of ProQR Therapeutics worth $323K as of Q2 2026.
GSA Capital Partners bought 59,588 ProQR Therapeutics shares in Q2 2026, an estimated $98.1K.
ProQR Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1257 holding.
GSA Capital Partners first reported a position in ProQR Therapeutics in Q3 2019 and has held it in 11 quarters since.
GSA Capital Partners's ProQR Therapeutics position peaked at $1.15M in Q3 2021.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.